![Tuberculosis Diagnostics: The Promise of [18F]FDT PET Imaging](https://res.cloudinary.com/healthmanagement-org/image/upload/c_thumb,f_auto,fl_lossy,h_184,q_90,w_500/v1721132076/cw/00127782_cw_image_wi_88cc5f34b1423cec414436d2748b40ce.webp "Tuberculosis Diagnostics: The Promise of [18F]FDT PET Imaging")
Florida Cancer Specialists & Research Institute, LLC (FCS) is pleased to welcome newly appointed members, Pareshkumar (Paresh) Patel, MD and Andres Soriano, MD, to its Executive Board, effective January 1, 2023.
Quadruple board-certified in medical oncology, hematology, internal medicine, hospice and palliative care, Dr. Paresh Patel provides care to patients out of the FCS Tallahassee Cancer Center. Previously holding the Vice Chair position, Dr. Patel will now serve as the Quality Committee Chair on the FCS Executive Board. In addition to his new appointment, Dr. Patel is the recipient of the 2021 FLASCO “Advocate of the Year” award, the current president of the Capital Medical Society, and has been elected to serve on the 2023 Community Oncology Alliance (COA) Board.
Dr. Andres Soriano is triple board-certified in hematology, oncology and internal medicine and currently cares for patients at FCS Englewood and Venice HealthPark locations. Dr. Soriano is active in clinical trial research, having a special interest in Phase 1 clinical trials. This will be Dr. Soriano’s first term serving the FCS Executive Board.
“Dr. Patel and Dr. Soriano are exemplary physicians and leaders both within FCS and in the medical and oncology communities. It is an honor and a privilege to have them serve on our Executive Board,” remarked FCS President & Managing Physician Michael Diaz, MD.
In addition to its newest members, FCS Chief Medical Officer of Therapeutics & Analytics Lucio N. Gordan, MD will remain Chair Emeritus and Noel A Maun, MD, PhD, current FCS Compliance Committee Chair and Disciplinary & Ethics Co-Chair, concludes his service on the Executive Board.
“We are grateful for Dr. Maun’s service to our Executive Board over many years and offer our appreciation for the generous time Dr. Gordan continues to commit to the important work being done,” adds Dr. Diaz.
“FCS continues to position itself as a global oncology leader, expanding upon innovative technology and treatments and making them available to patients. Our Executive Board is critical to ensuring we can continue delivering the highest quality of care. We greatly value their leadership,” says FCS Chief Executive Officer Nathan H. Walcker.
Source: Florida Cancer Specialists & Research Institute, LLC (FCS)
